Innovative therapeutics

Investors

Press Releases

 
Press Releases
  Date Title View
Jul 27, 2016
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10% No Clinically Relevant Sustained Rises in ALT Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval Filing Conference Call and Web-cast with Slides to be...
Jul 21, 2016
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene transfer in severe Hemophilia will be presented at the XXXII International Congress of the World Federation of Hemophilia.  BM...
Jul 18, 2016
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of two biopharmaceutical veterans to its Board of Directors: Willard Dere, M.D., Professor of Internal Medicine at the University of U...
Jul 14, 2016
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 4, at 4:30 p.m. ET to discuss second quarter 2016 financial results and pr...
Jun 20, 2016
SAN RAFAEL, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the upcoming oral presentation summarizing a late breaking abstract accepted for the XXXII International Congress of the World Federation of Hemophilia.  The presentation will report interim results of an open-la...
May 31, 2016
SAN RAFAEL, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has withdrawn its Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) following discussions at the May 2016 Committee for Medicinal Products for H...
May 4, 2016
- Bank of America Merrill Lynch 2016 Health Care Conference on May 11 in Las Vegas  - Goldman Sachs 37th Annual Global Healthcare Conference on June 9 in Ranchos Palos Verdes, California SAN RAFAEL, Calif., May 04, 2016 (GLOBE NEWSWIR...
May 3, 2016
EU and U.S. Marketing Application Submissions Planned for Mid-Year 2016 Company Seeking Priority Review in the U.S. SAN RAFAEL, Calif., May 03, 2016 (GLOBE NEWSWIRE) --  BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the European Medicines Agency (EMA...
Apr 28, 2016
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million -Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $315 to $340 million - Kuvan Net Product Re...
Apr 21, 2016
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide der...
Page:
1
... NextLast
= add release to Briefcase
img_bottom-content

Diseases

MPS I, MPS VI, PKU, LEMS, Lysosomal Storage Disorders, Morquio A/MPS IVA

Products

VIMIZIM™, Kuvan®, Naglazyme®, Aldurazyme®, Firdapse®

Patient/Physician Contact Information

BioMarin Patient and Physician Support (BPPS)
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: bpps@bmrn.com

Top